Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117309 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL11695805 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL2341027 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL2178335 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL50789 | 1.00 | — | — | |
| SCHEMBL4195383 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Hexane SCHEMBL25218797 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL2175777 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL10320275 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL134259 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2933246-B1 | VERSATILE AND FUNCTIONALISED INTERMEDIATES FOR THE SYNTHESIS OF VITAMIN D AND NOVEL VITAMIN D DERIVATIVES | ENDOTHERM GMBH (DE) | 2020-01-08 | — | — | EP | disclosed |
| US-9994508-B2 | Versatile and functionalised intermediates for the synthesis of vitamin D and novel vitamin D derivatives | ENDOTHERM GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20150344421-A1 | Versatile and Functionalised Intermediates for the Synthesis of Vitamin D and Novel Vitamin D Derivatives | ENDOTHERM GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| EP-2933246-A1 | VERSATILE AND FUNCTIONALISED INTERMEDIATES FOR THE SYNTHESIS OF VITAMIN D AND NOVEL VITAMIN D DERIVATIVES | Endotherm GmbH (DE) | 2015-10-21 | — | — | EP | disclosed |
| EP-1245591-B1 | METHOD FOR HYDROGENATION OF DIENE POLYMERS AND COPOLYMERS | ASAHI CHEMICAL IND (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344421-A1 | Versatile and Functionalised Intermediates for the Synthesis of Vitamin D and Novel Vitamin D Derivatives | VDR, CYP24A1, CYP2R1 | TSHR 1643/4885THRB 1238/4885DNM1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.